Perspectives on dyslipidemia and coronary heart disease in women

Area of Science:

• Cardiovascular Medicine
• Women's Health
• Lipidology

Background:

• Coronary heart disease (CHD) is the primary cause of mortality in American women.
• Significant disparities exist in CHD pathology, incidence, and prevalence across age groups and between sexes.
• Lipoprotein levels and lipid profiles are critical determinants of CHD risk in women.

Purpose of the Study:

• To review the complex interplay of hormonal influences, lifestyle factors, and comorbidities on lipid profiles in women.
• To assess the current representation of women in clinical trials for CHD prevention and lipid-lowering therapies.
• To evaluate the efficacy and undertreatment of lipid-lowering therapies, particularly statins, in women.

Main Methods:

• Literature review of studies examining CHD in women across the life span.
• Analysis of hormonal influences on lipoprotein metabolism, including oral contraceptives and hormone replacement therapy.
• Examination of the impact of obesity, metabolic syndrome, and diabetes on lipid profiles and CHD risk.
• Review of clinical trial data regarding lifestyle interventions and pharmacologic lipid-lowering therapies in women.

Main Results:

• Hormonal fluctuations throughout a woman's life, influenced by medications, significantly affect lipid levels.
• Comorbidities like obesity, metabolic syndrome, and diabetes exacerbate adverse lipid profiles, increasing CHD risk.
• Women are underrepresented in clinical trials, and evidence suggests they are undertreated with lipid-lowering therapies despite demonstrated benefits from statins.

Conclusions:

• Optimal cardiovascular prevention and treatment strategies for women require further investigation due to data gaps.
• Addressing undertreatment and improving trial representation are crucial for advancing women's cardiovascular health.
• Further research is needed to tailor lipid management and lifestyle interventions for diverse female populations.